论文部分内容阅读
目的探讨血清癌胚抗原(CEA)和细胞角质蛋白(CYFRA21-1)水平对非小细胞肺癌化疗患者预后的预测价值。方法选择2012—2013年我院收治的非小细胞肺癌患者89例,均于第1、3个化疗周期前抽取患者清晨空腹静脉血2~3 ml,检测其血清CEA和CYFRA21-1水平。结果化疗后血清CEA水平下降≥19.8%的患者生存时间为(15.3±1.2)个月,长于血清CEA水平下降<19.8%的患者〔(9.8±1.4)个月〕(P<0.05);化疗后血清CYFRA21-1水平下降≥35.5%的患者生存时间为(17.4±2.1)个月,长于血清CYFRA21-1水平下降<35.5%的患者〔(10.8±1.8)个月〕(P<0.05)。结论血清CEA和CYFRA21-1水平下降程度与非小细胞肺癌化疗患者的预后有关。
Objective To investigate the predictive value of serum carcinoembryonic antigen (CEA) and cytokeratin (CYFRA21-1) in prognosis of non-small cell lung cancer patients undergoing chemotherapy. Methods Eighty-nine patients with non-small cell lung cancer admitted to our hospital from 2012 to 2013 were enrolled in this study. All patients were given 2 ~ 3 ml fasting venous blood before the first and third cycles of chemotherapy. The levels of serum CEA and CYFRA21-1 were measured. Results The survival time was (15.3 ± 1.2) months in patients with a serum CEA level of ≥19.8% after chemotherapy, and (9.8 ± 1.4) months longer than those with a serum CEA level decrease of <19.8% (P <0.05) Patients with a serum CYFRA21-1 level of ≥35.5% had a mean survival time of (17.4 ± 2.1) months, (10.8 ± 1.8) months (P <0.05) longer than those with serum levels of CYFRA21-1 <35.5%. Conclusions The decrease of serum CEA and CYFRA21-1 levels is related to the prognosis of non-small cell lung cancer patients undergoing chemotherapy.